Literature DB >> 29224808

Delayed clinical complete response to intensity-modulated radiotherapy in nasopharyngeal carcinoma.

Wen-Fei Li1, Yuan Zhang1, Xu Liu1, Ling-Long Tang1, Li Tian2, Rui Guo1, Li-Zhi Liu2, Ying Sun1, Jun Ma3.   

Abstract

OBJECTIVE: Twelve weeks after radiotherapy is the recommended time-point for assessing tumor response in nasopharyngeal carcinoma (NPC); however, regression after 12 weeks remains unclear. We explored NPC regression and the prognosis of patients with delayed clinical complete response (cCR).
MATERIALS AND METHODS: MRI images of 556 NPC patients treated with intensity-modulated radiotherapy (IMRT) between 2009 and 2012 were retrospectively reviewed. Clinical tumor response was assessed at 3-4 (assessment 1) and 6-9 months (assessment 2) after IMRT, and survival rates were compared.
RESULTS: Of the 556 patients, 463 (83.3%) had cCR at assessment 1 (early cCR). Of the 93 patients with partial response at assessment 1, 45 (48.4%) achieved cCR at assessment 2 (delayed cCR), and 48 did not have cCR at assessment 2 (non-cCR). Locoregional failure rate was lower in patients with a cCR than those without a cCR at assessment 1 (7.1% vs. 26.9%, P < .001) and assessment 2 (7.1% vs. 45.8%, P < .001). Multivariate analysis showed cCR was a favorable prognostic factor for locoregional failure-free survival (LRFFS), failure-free survival (FFS), and overall survival (OS). Early and delayed cCR groups had better 5-year LRFFS (92.6% vs. 93.3% vs. 54.2%), FFS (83.8% vs. 84.4% vs. 48.5%) and OS (92.1% vs. 90.6% vs. 65.4%) than the non-cCR group (all P < .001).
CONCLUSIONS: Nearly half of the patients with partial response at 3-4 months achieve cCR by 6-9 months; delayed cCR is not a poor prognosticator. We suggest later assessment of cCR at 6-9 months after IMRT is acceptable in responding NPC.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clinical complete response; Intensity-modulated radiotherapy; Nasopharyngeal carcinoma; Prognosis

Mesh:

Year:  2017        PMID: 29224808     DOI: 10.1016/j.oraloncology.2017.10.020

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  3 in total

1.  Value of early evaluation of treatment response using 18F-FDG PET/CT parameters and the Epstein-Barr virus DNA load for prediction of outcome in patients with primary nasopharyngeal carcinoma.

Authors:  Yu-Hung Chen; Kai-Ping Chang; Sung-Chao Chu; Tzu-Chen Yen; Ling-Yi Wang; Joseph Tung-Chieh Chang; Cheng-Lung Hsu; Shu-Hang Ng; Shu-Hsin Liu; Sheng-Chieh Chan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-27       Impact factor: 9.236

2.  Hopkins criteria for residual disease assessment after definitive radiotherapy in nasopharyngeal carcinoma.

Authors:  Yang Liu; Wen Long; Guannan Wang; Yuxiang Yang; Biaoshui Liu; Wei Fan
Journal:  Cancer Med       Date:  2019-12-25       Impact factor: 4.452

3.  Utility of magnetic resonance imaging in determining treatment response and local recurrence in nasopharyngeal carcinoma treated curatively.

Authors:  Katherine Meng; Jeremy Tey; Francis Cho Hao Ho; Hira Asim; Timothy Cheo
Journal:  BMC Cancer       Date:  2020-03-06       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.